Biotechnology Companies By Roa

Return On Asset
Return On AssetEfficiencyMarket RiskExp Return
1OCUP Ocuphire Pharma
0.53
(0.06)
 2.89 
(0.17)
2VYGR Voyager Therapeutics
0.3
 0.06 
 4.65 
 0.28 
3ZYME Zymeworks Common Stock
0.3
 0.16 
 3.00 
 0.48 
4IRWD Ironwood Pharmaceuticals
0.13
 0.00 
 5.47 
 0.00 
5VRTX Vertex Pharmaceuticals
0.13
 0.16 
 2.03 
 0.32 
6ALKS Alkermes Plc
0.13
 0.08 
 2.89 
 0.24 
7CPRX Catalyst Pharmaceuticals
0.13
 0.05 
 3.69 
 0.17 
8HALO Halozyme Therapeutics
0.12
 0.01 
 2.41 
 0.02 
9PLX Protalix Biotherapeutics
0.12
 0.06 
 3.14 
 0.18 
10MDXG MiMedx Group
0.11
 0.03 
 2.62 
 0.07 
11BNTX BioNTech SE
0.11
(0.08)
 2.18 
(0.17)
12UTHR United Therapeutics
0.11
(0.05)
 1.63 
(0.09)
13ARCT Arcturus Therapeutics Holdings
0.1
 0.21 
 4.34 
 0.89 
14GMAB Genmab AS
0.1
(0.11)
 2.10 
(0.23)
15GILD Gilead Sciences
0.0931
(0.06)
 1.83 
(0.11)
16NBIX Neurocrine Biosciences
0.0878
 0.13 
 1.63 
 0.20 
17PBYI Puma Biotechnology
0.0865
 0.18 
 5.38 
 0.96 
18INDV Indivior PLC Ordinary
0.0862
 0.11 
 4.48 
 0.47 
19REGN Regeneron Pharmaceuticals
0.0849
 0.25 
 1.11 
 0.27 
20MEIP MEI Pharma
0.083
(0.24)
 2.84 
(0.67)
The analysis above is based on a 90-day investment horizon and a default level of risk. Use the Portfolio Analyzer to fine-tune all your assumptions. Check your current assumptions here.
Return on Asset or ROA shows how effective is the management of the company in generating income from utilizing all of the assets at their disposal. It is a useful ratio to evaluate the performance of different departments of a company as well as to understand management performance over time. Return on Asset measures overall efficiency of a company in generating profits from its total assets. It is expressed as the percentage of profits earned per dollar of Asset. A low ROA typically means that a company is asset-intensive and therefore will needs more money to continue generating revenue in the future.